Stimulant use disorders represent an important research opportunity within the Addictions Therapeutics Market because approved pharmacotherapies remain limited compared with opioid, alcohol, and tobacco use disorders. SAMHSA notes that there are currently no FDA-approved medications specifically intended to prevent return to use for substances such as methamphetamine and cocaine.  The...